The company developed the first Korean cell culture-based trivalent influenza vaccine in 2015,​ followed by the first cell culture-based quadrivalent influenza vaccine, the second shingles vaccine, and Korea's second varicella vaccine. Additionally SK bioscience has developed South Korea's first COVID-19 vaccine, 'SKYCovione' through global cooperation with the Bill & Melinda Gates Foundation, CEPI and GSK.

The company is expanding its R&D pipeline through global partnerships with public and private institutions, and is planning to commercialize a pneumococcal conjugate vaccine, cervical cancer vaccine, typhoid conjugate vaccine, and rotavirus vaccine.